Prognia
Drug Database
🇪🇺EU · EMAApplication withdrawnATC: B02BD08

HemAryo(eptacog alfa (activated))

Hemophilia A;Hemophilia B;Factor VII Deficiency

Marketing Authorisation Holder: UGA Biopharma

INN: eptacog alfa (activated)

Indication

Treatment of bleeding episodes and for the prevention of bleeding.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about HemAryo — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.